Release Date: March 28, 2023
Expiration Date: March 28, 2024

Target Audience
Community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with EGFR-altered NSCLC

Learning Objectives
After participating in this activity, participants should be better able to: 

• Assess current testing guidelines for patients diagnosed with metastatic NSCLC, including recommendations for EGFR and MET testing
• Evaluate current therapies available for patients with NSCLC that harbor EGFR mutations and alterations, including safety and efficacy results from pivotal clinical trials
• Identify mitigation strategies to combat treatment-related adverse events that may occur with the use of EGFR-directed therapies, and educate patients and caregivers regarding these adverse events

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Topics of Discussion
Module 1: Testing Guidelines for Patients With Metastatic NSCLC
Module 2: Treating Patients With EGFR Mutant NSCLC
Module 3: Adverse Event Management Strategies
Module 4: Patient/Caregiver Education

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Anne Tsao, MD
Vice President, Academic Affairs
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
MD Anderson Cancer Center
Houston, Texas

Grant/Research Support: Ariad, Astra Zeneca, BMS, Boehringer-Ingelheim, Eli Lilly, Epizyme, Genetech, Merck, Millennium, Novartis, Polaris, Seattle Genetics

Consultant/Advisory Board: Ariad, AstraZeneca, BMS, Boehringer-Ingelheim, Eli Lilly, EMD Serono, Genentech, GSK, Merck, Novartis, Pfizer, Roche, Seattle Genetics

Meghan Mooradian, MD
Instructor of Medicine
Harvard Medical School
Clinical Oncologist, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Speakers’ Bureau, Honoraria for non-CME: Bristol Myers Squibb
Consultant/Advisory Board: AstraZeneca, Bristol Myers Squibb, Xilio Therapeutics, Istari Oncology

Kelly Goodwin, MSN, RN, ANP-BC
Adult Care Nurse Practitioner
Massachusetts General Hospital
Boston, Massachusetts

No relevant financial disclosures

Ivy Elkins
Lung Cancer Patient and Advocate
Co-Founder EGFR Resisters

Consultant/Advisory Board: AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, BMS, Daiichi, Gilead, Janssen, Merck, Mirati

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Support
This activity is supported by an independent educational grant from Boehringer Ingelheim.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.